{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-100444","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.272844+00:00","generated_at":"2026-06-29T21:48:49.719110+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Black Diamond appoints interim CMO and new CSO; CMO and CSO depart","bullets":["Karsten Witt appointed Interim CMO, effective Aug 4, 2021, succeeding Rachel Humphrey.","Rachel Humphrey offered separation agreement with severance, advisory role until Feb 28, 2022; vested option extension.","Elizabeth Buck appointed Chief Scientific Officer, effective Aug 11, 2021, succeeding Christopher Roberts.","Christopher Roberts resigned to become CEO at another company; will serve as advisor post-departure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-100444","json":"https://secwatch.observer/filing/0001104659-21-100444.json","markdown":"https://secwatch.observer/filing/0001104659-21-100444.md","text":"https://secwatch.observer/filing/0001104659-21-100444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921100444/0001104659-21-100444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921100444/tm2123993d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:48:49.719110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"024b7bd46d","claim":"Elizabeth Buck was appointed as Chief Scientific Officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Effective August 11 , 2021, Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921100444/0001104659-21-100444-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"5716a5edb7","claim":"Karsten Witt was appointed as Interim Chief Medical Officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921100444/0001104659-21-100444-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"b6afb75fc0","claim":"Rachel Humphrey departed as Chief Medical Officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921100444/0001104659-21-100444-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"fb56a1d42f","claim":"Christopher Roberts resigned as Chief Scientific Officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921100444/0001104659-21-100444-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}